英國批准阿斯利康(AZN.US)新冠抗體雞尾酒療法Evusheld
格隆匯3月18日丨英國藥品和保健品監管局(MHRA)3月17日發佈消息稱,批准阿斯利康公司基於抗體的新型冠狀病毒治療方法Evusheld用於免疫反應較差的成年人。消息稱,在試驗中,英國-瑞典醫藥公司阿斯利康的Evusheld抗體雞尾酒療法可將出現新冠症狀的風險降低77%,單劑注射後的保護作用至少可持續6個月。Evusheld是tixagevimab和cilgavimab兩種長效抗體的組合。去年年底,美國FDA批准Evusheld緊急使用授權申請,用於SARS-CoV-2暴露前的預防。這是FDA批准的首個用於COVID-19暴露前預防的抗體療法。英國監管機構同時警吿稱,目前還沒有足夠的數據來全面評估Evusheld對奧密克戎變體的有效性以及保護時效。該部門就此與阿斯利康保持聯繫。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.